Again, IMO, I disagree. I am inclined to believe that a BP partnership would come shortly after data and that partner would not necessarily give a huge upfront payment, but would pay the bills to get LymPro through the FDA approval process over the next year or so leading up to a specific reimbursement code for LymPro so that Medicare could then cover. That partner would obviously want to see final data before any deal was done.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links